These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 19138379)

  • 1. Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects.
    Møss J; Scharling B; Ezban M; Møller Sørensen T
    J Thromb Haemost; 2009 Feb; 7(2):299-305. PubMed ID: 19138379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clearance of rFVIIa and NN1731 after intravenous administration to Beagle dogs.
    Agersø H; Kristensen NR; Østergaard H; Karpf DM; Hermit MB; Pelzer H; Petersen LC; Ezban M
    Eur J Pharm Sci; 2011 Apr; 42(5):578-83. PubMed ID: 21382491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravascular inhibition of factor VIIa and the analogue NN1731 by antithrombin.
    Petersen LC; Karpf DM; Agersø H; Hermit MB; Pelzer H; Persson E; Nichols TC; Ezban M
    Br J Haematol; 2011 Jan; 152(1):99-107. PubMed ID: 21083658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects.
    Møss J; Rosholm A; Laurén A
    J Thromb Haemost; 2011 Jul; 9(7):1368-74. PubMed ID: 21575130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a recombinant FVIIa analogue, NN1731, on blood loss and survival after liver trauma in the pig.
    Zaar M; Secher NH; Johansson PI; Vainer B; Ezban M; Agersø H; Madsen PL; Lomholt N; Hermit MB; Lauritzen B
    Br J Anaesth; 2009 Dec; 103(6):840-7. PubMed ID: 19808774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects.
    Fridberg MJ; Hedner U; Roberts HR; Erhardtsen E
    Blood Coagul Fibrinolysis; 2005 Jun; 16(4):259-66. PubMed ID: 15870545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor VIII activation by factor VIIa analog (V158D/E296V/M298Q) in tissue factor-independent mechanisms.
    Ogiwara K; Nogami K; Shima M
    Thromb Haemost; 2011 Oct; 106(4):665-74. PubMed ID: 21901232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A.
    Sørensen B; Persson E; Ingerslev J
    Br J Haematol; 2007 Apr; 137(2):158-65. PubMed ID: 17391496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 dose-escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXa
    Parsons-Rich D; Hua F; Li G; Kantaridis C; Pittman DD; Arkin S
    J Thromb Haemost; 2017 May; 15(5):931-937. PubMed ID: 28294526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation.
    Bysted BV; Scharling B; Møller T; Hansen BL
    Haemophilia; 2007 Sep; 13(5):527-32. PubMed ID: 17880439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant activated factor VII in spinal surgery: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial.
    Sachs B; Delacy D; Green J; Graham RS; Ramsay J; Kreisler N; Kruse P; Khutoryansky N; Hu SS
    Spine (Phila Pa 1976); 2007 Oct; 32(21):2285-93. PubMed ID: 17906567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers.
    Cardinal M; Kantaridis C; Zhu T; Sun P; Pittman DD; Murphy JE; Arkin S
    J Thromb Haemost; 2018 Sep; 16(9):1722-1731. PubMed ID: 29908043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity.
    Hoffman M; Volovyk Z; Persson E; Gabriel DA; Ezban M; Monroe DM
    J Thromb Haemost; 2011 Apr; 9(4):759-66. PubMed ID: 21294824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects.
    Namour F; Vanhoutte FP; Beetens J; Blockhuys S; De Weer M; Wigerinck P
    Drugs R D; 2012 Sep; 12(3):141-63. PubMed ID: 22950522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombin generation and platelet activation induced by rFVIIa (NovoSeven) and NN1731 in a reconstituted cell-based model mimicking haemophilia conditions.
    Aljamali MN; Kjalke M; Hedner U; Ezban M; Tranholm M
    Haemophilia; 2009 Nov; 15(6):1318-26. PubMed ID: 19659796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers.
    Verhamme P; Pakola S; Jensen TJ; Berggren K; Sonesson E; Saint-Remy JM; Balchen T; Belmans A; Cahillane G; Stassen JM; Peerlinck K; Glazer S; Jacquemin M
    Clin Ther; 2010 Jun; 32(6):1205-20. PubMed ID: 20637972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors.
    Ljung R; Karim FA; Saxena K; Suzuki T; Arkhammar P; Rosholm A; Giangrande P;
    J Thromb Haemost; 2013 Jul; 11(7):1260-8. PubMed ID: 23578227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients.
    Brophy DF; Martin EJ; Nolte ME; Kuhn JG; Carr ME
    Haemophilia; 2007 Sep; 13(5):533-41. PubMed ID: 17880440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. rFVIIa and NN1731 reduce bleeding in hydroxyethyl starch hemodiluted rabbits.
    Lauritzen B; Viuff D; Tranholm M; Ezban M
    J Trauma; 2010 Nov; 69(5):1196-202. PubMed ID: 20032791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.